Malaria vaccines to moderate the impact of antibiotic resistance in endemic countries

References

1. WHO 10 global health issues to track in 2021. n.d https://www.who.int/news486 room/spotlight/10-global-health-issues-to-track-in-2021 accessed 28 February 2022
2. Murray CJL, Ikuta KS, Sharara F. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 2022; 399:629–655 [View Article] [PubMed]
   [Google Scholar]
3. Cantón R, Bryan J. Global antimicrobial resistance: from surveillance to stewardship. Part 1: surveillance and risk factors for resistance. Expert Rev Anti Infect Ther 2012; 10:1269–1271 [View Article] [PubMed]
   [Google Scholar]
4. Wernli D, Jørgensen PS, Parmley EJ, Troell M, Majowicz S et al. Evidence for action: a one Health learning platform on interventions to tackle antimicrobial resistance. Lancet Infect Dis 2020; 20:e307–e311 [View Article] [PubMed]
   [Google Scholar]
5. O’Neill J. Tackling drug-resistant infections globally: final report and recommendations; 2016 http://amr-review.org/home
6. WHO Resolution 72·5–antimicrobial resistance; 2019 https://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_R5-en.pdf accessed 11 May 2022
7. Micoli F, Bagnoli F, Rappuoli R, Serruto D. The role of vaccines in combatting antimicrobial resistance. Nat Rev Microbiol 2021; 19:287–302 [View Article] [PubMed]
   [Google Scholar]
8. Lipsitch M, Siber GR, Klugman KP, Collier RJ. How can vaccines contribute to solving the antimicrobial resistance problem?. mBio 2022; 7:e00428-16 [View Article] [PubMed]
   [Google Scholar]
9. Maze MJ, Bassat Q, Feasey NA, Mandomando I, Musicha P et al. The epidemiology of febrile illness in sub-Saharan Africa: implications for diagnosis and management. Clin Microbiol Infect 2018; 24:808–814 [View Article] [PubMed]
   [Google Scholar]
10. Tedijanto C, Olesen SW, Grad YH, Lipsitch M. Estimating the proportion of bystander selection for antibiotic resistance among potentially pathogenic bacterial flora. Proc Natl Acad Sci 2018; 115:E11988–E11995 [View Article] [PubMed]
    [Google Scholar]
11. Cassiolato AP, Almeida SCG, Andrade AL, Minamisava R, Brandileone M de C. Expansion of the multidrug-resistant clonal complex 320 among invasive Streptococcus pneumoniae serotype 19A after the introduction of a ten-valent pneumococcal conjugate vaccine in Brazil. PLoS One 2018; 13:e0208211 [View Article] [PubMed]
    [Google Scholar]
12. World Malaria Report 2018. Geneva, Switzerland: World Health Organization; 2018
13. Kakar Q, Khan MA, Bile KM. Malaria control in Pakistan: new tools at hand but challenging epidemiological realities. East Mediterr Health J 2010; 16 Suppl:S54–S60 [View Article] [PubMed]
    [Google Scholar]
14. WHO World malaria report 2018. World Health Organization 2019. n.d https://apps.who.int/iris/bitstream/handle/10665/275867/9789241565653- eng.pdf?ua
15. Jawaid A, Zafar AM, Mahmood SF. Impact of Afghan refugees on the infectious disease profile of Pakistan: beyond economy. Int J Infect Dis 2008; 12:e131 [View Article] [PubMed]
    [Google Scholar]
16. Monge-Maillo B, López-Vélez R. Migration and malaria risk health, risk & society. Mediter J Hematol Infectdis 2012; 4: [View Article] [PubMed]
    [Google Scholar]
17. Nuwaha F. The challenge of chloroquine-resistant malaria in sub-Saharan Africa. Health Policy Plan 2001; 16:1–12 [View Article] [PubMed]
    [Google Scholar]
18. Laurens MB. RTS,S/AS01 vaccine (Mosquirix). In Human Vaccines & Immunotherapeutics vol 16 2020 pp 480–489 [View Article] [PubMed]
    [Google Scholar]
19. Jansen KU, Knirsch C, Anderson AS. The role of vaccines in preventing bacterial antimicrobial resistance. Nat Med 2018; 24:10–19 [View Article] [PubMed]
    [Google Scholar]
20. Centers for Disease Control and Prevention. Barriers to Developing a Malaria Vaccine Centers for Disease Control and Prevention; 2021 https://www.cdc.gov/malaria/malaria_worldwide/reduction/vaccine.html#:~:text=The %20development%20of%20a%20malaria,immune%20response%20
21. WHO WHO recommends groundbreaking malaria vaccine for children at risk recommends-groundbreaking malaria-vaccine-for-children-at-risk; 2021 https://www.WHO.int/news/item/06-10-2021-WHO- accessed 12 May 2022
22. Praet N, Asante KP, Bozonnat M-C, Akité EJ, Ansah PO et al. Assessing the safety, impact and effectiveness of RTS,S/AS01_E malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up. Malar J 2022; 21:132 [View Article] [PubMed]
    [Google Scholar]
23. RTS,S Clinical Trials Partnership Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015; 386:31–45 [View Article] [PubMed]
    [Google Scholar]
24. Guerra Mendoza Y, Garric E, Leach A, Lievens M, Ofori-Anyinam O et al. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa. Hum Vaccin Immunother 2019; 15:2386–2398 [View Article] [PubMed]
    [Google Scholar]
25. Tables of malaria vaccine projects globally Geneva: World Health Organization. n.d https://www.who.int/immunization/research/development/Rainbow_tables/en accessed 14 July 2019
26. Draper SJ, Sack BK, King CR, Nielsen CM, Rayner JC et al. Malaria vaccines: recent advances and new horizons. Cell Host Microbe 2018; 24:43–56 [View Article] [PubMed]
    [Google Scholar]